Thomas Grellety

Follow

Generating author description...

All published works

Action	Title	Year	Authors
+	Encouraging Trends in Modern Phase 1 Oncology Trials	2018	Camille Chakiba Thomas Grellety Carine Bellera A. Italiano
+ PDF Chat	Risks and benefits of phase 1 oncology trials in the era of personalized medicine	2016	Camille Chakiba Thomas Grellety Sophie Cousin Antoîne Italiano
+ PDF Chat	Quality of reporting of phase II trials: a focus on highly ranked oncology journals	2014	Thomas Grellety Aurélie Petit-Monéger Abou Diallo Simone Mathoulin‐Pélissier Antoîne Italiano

Common Coauthors

Coauthor	Papers Together
Antoîne Italiano	2
Camille Chakiba	2
Carine Bellera	1
Sophie Cousin	1
Simone Mathoulin‐Pélissier	1
Abou Diallo	1
A. Italiano	1
Aurélie Petit-Monéger	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Content and Quality of Currently Published Phase II Cancer Trials	2000	Luigi Mariani Ettore Marubini	1
+	Five-year change in statistical designs of phase II trials published in leading cancer journals	2004	Simon Thézenas Jacqueline Duffour Stéphane Culine A. Kramar	1
+	Optimising the design of phase II oncology trials: The importance of randomisation	2008	Mark J. Ratain Daniel J. Sargent	1
+ PDF Chat	Randomized Phase II Trials: Time for a New Era in Clinical Trial Design	2010	Sumithra J. Mandrekar Daniel J. Sargent	1
+	The unclear zone in phase II clinical trials	2010	S. M. Allegro Gregory R. Pond Sébastien J. Hotte	1
+	Providing Protocol Information for <i>Journal of Clinical Oncology</i> Readers: What Practicing Clinicians Need to Know	2011	Daniel G. Haller Stephen A. Cannistra	1
+ PDF Chat	The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee	2010	Lesley Seymour S. Percy Ivy Daniel J. Sargent David R. Spriggs Laurence Baker Larry Rubinstein Mark J. Ratain M Blanc David B. Stewart John Crowley	1
+	Phase II Trials in <i>Journal of Clinical Oncology</i>	2009	Stephen A. Cannistra	1
+	Novel Designs and End Points for Phase II Clinical Trials	2009	Alex A. Adjei Michaele C. Christian Percy Ivy	1
+ PDF Chat	GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies—reporting of phase 1 and phase 2 clinical trials	2005	Susan M. Chang Sharon L. Reynolds Nicholas Butowski Kathleen R. Lamborn Jan C. Buckner Richard Kaplan Darell D. Bigner	1
+ PDF Chat	Phase II studies of anticancer chemotherapy: indirect evidence of poor quality	2006	Alessandro Ottaiano Gaetano Facchini Guglielmo Nasti Alfredo Budillon Michele Caraglia	1
+ PDF Chat	Quality of Randomized Controlled Trials Reporting in the Primary Treatment of Brain Tumors	2006	Rose Lai Rong Chu Michael Fraumeni Lehana Thabane	1
+ PDF Chat	SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials	2013	An‐Wen Chan Jennifer Tetzlaff Douglas G. Altman Andreas Laupacis Peter C Gøtzsche Karmela Krleža-Jerić Asbjørn Hróbjartsson Howard Mann Kay Dickersin Jesse A. Berlin	1
+	Responses and toxic deaths in Phase I clinical trials	1990	Genevieve Decoster Gerburg M. Stein E. E. Holdener	1